Pembrolizumab plus enfortumab vedotin in urothelial cancer

Matteo Santoni¹, Hideki Takeshita², Francesco Massari^{3

4}, Aristotelis Bamias⁵, Linda Cerbone⁶, Ondrej Fiala^{7

8}, Veronica Mollica^{9

10}, Sebastiano Buti¹¹, Angela Santoni¹², Joaquim Bellmunt¹³

Affiliations

¹ Oncology Unit, Macerata Hospital, Macerata, Italy.
² Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
³ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. fmassari79@gmail.com.
⁴ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. fmassari79@gmail.com.
⁵ 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
⁶ Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.
⁷ Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
⁸ Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
⁹ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
¹⁰ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
¹¹ Medical Oncology Unit, University Hospital of Parma - Department of Medicin and Surgery, University of Parma, Parma, Italy.
¹² Department of Molecular Medicine, Sapienza University, Rome Italian Pasteur Institute, Cenci-Bolognetti Foundation, Rome, Italy.
¹³ Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Matteo Santoni et al. Nat Rev Urol. 2024 Jul.

. 2024 Jul;21(7):387-388.

doi: 10.1038/s41585-024-00858-y.

¹ Oncology Unit, Macerata Hospital, Macerata, Italy.
² Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
³ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. fmassari79@gmail.com.
⁴ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. fmassari79@gmail.com.
⁵ 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
⁶ Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.
⁷ Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
⁸ Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
⁹ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
¹⁰ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
¹¹ Medical Oncology Unit, University Hospital of Parma - Department of Medicin and Surgery, University of Parma, Parma, Italy.
¹² Department of Molecular Medicine, Sapienza University, Rome Italian Pasteur Institute, Cenci-Bolognetti Foundation, Rome, Italy.
¹³ Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

No abstract available

References

1. Powles, T. B. et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann. Oncol. 34 (Suppl. 2), S1340 (2023). - DOI
1. Chikuma, S. et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell energy? in vivo. J. Immunol. 182, 6682–6689 (2009). - DOI - PubMed
1. Milella, M. et al. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. Br. J. Cancer 79, 770–779 (1999). - DOI - PubMed - PMC
1. Sakatani, T. et al. IFN-gamma expression in the tumor microenvironment and CD8-positive tumor-infiltrating lymphocytes as prognostic markers in urothelial cancer patients receiving pembrolizumab. Cancers 14, 263 (2022). - DOI - PubMed - PMC
1. Baker, S. C. et al. The urothelial transcriptomic response to interferon gamma: implications for bladder cancer prognosis and immunotherapy. Cancers 14, 5295 (2022). - DOI - PubMed - PMC